TREATMENT OF MILD HYPERTENSION

这种竞争性延续的目标是（1）完成 对血压影响研究的一年随访， 认知和生活质量（情感、焦虑、性功能和 与非亲脂性β受体阻滞剂相比， 药物干预（当前研究）和（2） 完成对认知和生活质量的影响的研究， 与亲脂性β受体阻滞剂相比， blocker和placebo（新研究）。 目前的研究是 比较普萘洛尔（与安慰剂）和非药物 干预（vs无干预）2 × 2设计。 摊款 基线以及3个月和12个月包括血压（诊所和 门诊），认知，抑郁，焦虑，性兴趣和 功能，A型，愤怒和其他副作用。 共300 受试者将于1988年1月随机分组，为期一年， 1989年1月完成随访。 3-月份数据显示主要 普萘洛尔对血压的影响，副作用，以及一些 认知功能 非药物干预 显示了对尿钠和运动趋势的主要影响。 药物与非药物之间存在显著的交互作用。 对血压的药物干预。 因为β受体阻滞剂的脂溶性是一个关键决定因素， 药物在全身的分布，随访 研究将在随机双盲方案中比较 亲脂性β受体阻滞剂（普萘洛尔）与疏脂性β受体阻滞剂 （阿替洛尔）和安慰剂在3个月的时间内。 共有50 受试者将被随机分配至每组， 基线、2周和3个月。 招募和随机化 将于1988年6月开始（等待本申请的批准）， 将于1989年6月完成。

The goals of this competing continuation are (1) to complete the one-year follow-up of the study of the effects on blood pressure, cognition, and quality of life (affect, anxiety, sexual function and interest) of a lipophilic beta blocker compared to a non- pharmacological intervention (the Current Study) and (2) to complete a study of the effects on cognition, and quality of life of a lipophobic beta blocker in comparison to a lipophilic beta blocker and placebo (the New Study). The current study is comparing propranolol (vs placebo) and a non-pharmacological intervention (vs no intervention) in a 2 X 2 design. Assessments at baseline and 3 and 12 months include blood pressure (clinic and ambulatory), cognition, depression, anxiety, sexual interest and function, Type A, anger, and other side effects. A total of 300 subjects will be randomized by January 1988, with the one-year follow-up completed in January 1989. 3-month data indicate main effects of propranolol on blood pressure, side effects, and some cognitive functions. The non-pharmacologic intervention has shown a main effect on urinary sodium and trends for exercise. There is a significant interaction effect of drug and non- pharmacologic intervention on blood pressure. Because the liposolubility of beta blockers is a key determinant in the distribution of the drug throughout the body, the Follow-up Study will compare, in a randomized double-blind protocol, a lipophilic beta blocker (propranolol) with a lipophobic beta blocker (atenolol) and a placebo over a 3 month period. A total of 50 subjects will be randomized to each arm, with assessments at baseline, 2 weeks, and 3 months. Recruitment and randomization will begin in June 1988 (pending approval of this application) and be completed in June 1989.